Showing results (61-70 of 78) with videos related to

Sort By:
Pageof 8
Nature|January 12, 1995
Viral dynamics in human immunodeficiency virus type 1 infectionX Wei, S K Ghosh, M E Taylor, et al.
The Journal of Infectious Diseases|January 3, 2001
Phenotypic drug susceptibility testing predicts long-term virologic suppression better than treatment history in patients with human immunodeficiency virus infectionS A Call, M S Saag, A O Westfall, et al.
Biological Reviews of the Cambridge Philosophical Society|May 9, 2020
The role of the microbiome in the neurobiology of social behaviourAmar Sarkar, Siobhán Harty, Katerina V-A Johnson, et al.
Annals of Internal Medicine|August 1, 1996
Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. A randomized, double-blind, placebo-controlled trial. North American HIV Working PartyJ A Bartlett, S L Benoit, V A Johnson, et al.
The Journal of Infectious Diseases|May 1, 1995
Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. AIDS Clinical Trials Group 116B/117 Study Team and the Virology Committee Resistance Working GroupA J Japour, S Welles, R T D'Aquila, et al.
Antimicrobial Agents and Chemotherapy|May 1, 1993
Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Working GroupA J Japour, D L Mayers, V A Johnson, et al.
Annals of Internal Medicine|June 15, 1996
Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 InvestigatorsR T D'Aquila, M D Hughes, V A Johnson, et al.
Annals of Internal Medicine|March 15, 1995
Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working GroupR T D'Aquila, V A Johnson, S L Welles, et al.
Nature Ecology & Evolution|June 24, 2020
Microbial transmission in animal social networks and the social microbiomeAmar Sarkar, Siobhán Harty, Katerina V-A Johnson, et al.
Annals of Internal Medicine|June 15, 1997
Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy TeamM D Hughes, V A Johnson, M S Hirsch, et al.
Pageof 8